92 related articles for article (PubMed ID: 24992629)
1. Neoadjuvant treatment with dabrafenib of unresectable localizations from occult melanoma.
Rastrelli M; Pigozzo J; di Maggio A; Tosi AL; Sileni VC; Rossi CR
Melanoma Res; 2014 Aug; 24(4):413-4. PubMed ID: 24992629
[No Abstract] [Full Text] [Related]
2. Dabrafenib in the treatment of metastatic or unresectable melanoma.
Khoja L; Hogg D
Expert Rev Anticancer Ther; 2015 Mar; 15(3):265-76. PubMed ID: 25711514
[TBL] [Abstract][Full Text] [Related]
3. A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme.
Lau DK; Andrews MC; Turner N; Azad AA; Davis ID; Cebon JS
Melanoma Res; 2014 Apr; 24(2):144-9. PubMed ID: 24463460
[TBL] [Abstract][Full Text] [Related]
4. GSK drug combination approved for advanced melanoma.
Inman S
Am J Manag Care; 2014 Feb; 20(2 Spec No.):E10. PubMed ID: 25764581
[No Abstract] [Full Text] [Related]
5. Sweet syndrome in metastatic melanoma during treatment with dabrafenib and trametinib.
Scarfì F; Melotti B; Veronesi G; Ravaioli GM; Baraldi C; Lambertini M; Patrizi A; Dika E
Australas J Dermatol; 2019 Aug; 60(3):e242-e243. PubMed ID: 30724336
[No Abstract] [Full Text] [Related]
6. Pomalidomide, dabrafenib mesylate, and trametinib dimethyl sulfoxide.
Hussar DA; Kaminski JL
J Am Pharm Assoc (2003); 2013; 53(5):550-8. PubMed ID: 24030134
[No Abstract] [Full Text] [Related]
7. Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis.
Jeudy G; Dalac-Rat S; Bonniaud B; Hervieu A; Petrella T; Collet E; Vabres P
Br J Dermatol; 2015; 172(5):1454-5. PubMed ID: 25384395
[No Abstract] [Full Text] [Related]
8. Dabrafenib (Tafinlar) and trametinib (Mekinist) metastatic melanoma.
Med Lett Drugs Ther; 2013 Aug; 55(1422):62-3. PubMed ID: 23917385
[No Abstract] [Full Text] [Related]
9. Drug interaction between dabrafenib and immunosuppressive drugs: about one case.
Levavasseur M; Darras S; Mortier L; Goeminne C; Auffret M; Bertrand M
Melanoma Res; 2016 Oct; 26(5):532-4. PubMed ID: 27399255
[TBL] [Abstract][Full Text] [Related]
10. BRAF inhibitor activity in V600R metastatic melanoma.
Klein O; Clements A; Menzies AM; O'Toole S; Kefford RF; Long GV
Eur J Cancer; 2013 Mar; 49(5):1073-9. PubMed ID: 23237741
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapies: BREAKing a path for progress--dabrafenib confirms class effect.
Tawbi HA; Kirkwood JM
Nat Rev Clin Oncol; 2012 Sep; 9(9):496-7. PubMed ID: 22889973
[No Abstract] [Full Text] [Related]
12. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor.
Curry JL; Falchook GS; Hwu WJ; Torres-Cabala CA; Duvic M; Tetzlaff MT; Prieto VG
Am J Dermatopathol; 2013 Feb; 35(1):125-8. PubMed ID: 22878367
[TBL] [Abstract][Full Text] [Related]
13. Reply to the letters to the editor 'Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma' by Diwakar et al.
Schilling B; Sondermann W; Griewank KG; Livingstone E; Zimmer L; Hillen U; Schadendorf D
Ann Oncol; 2015 Jan; 26(1):250-251. PubMed ID: 25355721
[No Abstract] [Full Text] [Related]
14. Re: Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.
Diwakar D; Choi T; Tawbi TH; Kirkwood JM
Ann Oncol; 2014 Aug; 25(8):1670-1. PubMed ID: 24890848
[No Abstract] [Full Text] [Related]
15. [Dabrafenib: the new inhibitor of hyperactive B-RAF kinase].
Heneberg P
Klin Onkol; 2012; 25(5):333-9. PubMed ID: 23102194
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment with dabrafenib (GSK2118436) in a patient with ganglioglioma.
Shih KC; Shastry M; Williams JT; Jelsma PF; Abram SR; Ayyanar K; Burris HA; Infante JR
J Clin Oncol; 2014 Oct; 32(29):e98-e100. PubMed ID: 24516030
[No Abstract] [Full Text] [Related]
17. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.
Anforth RM; Blumetti TC; Kefford RF; Sharma R; Scolyer RA; Kossard S; Long GV; Fernandez-Peñas P
Br J Dermatol; 2012 Nov; 167(5):1153-60. PubMed ID: 22804352
[TBL] [Abstract][Full Text] [Related]
18. Melanoma: you can have your cake and eat it!
Hutchinson L
Nat Rev Clin Oncol; 2014 Jun; 11(6):301. PubMed ID: 24840077
[No Abstract] [Full Text] [Related]
19. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
20. Oncogene targeted therapy for metastatic primary scrotal melanoma.
Stocks B; Fuentes H; McDowell Z; Brooks M; Jones JA
Can J Urol; 2021 Apr; 28(2):10643-10647. PubMed ID: 33872566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
